Baxter BioPharma Solutions reports that it has finished the lyophilization capacity expansion at their cytotoxic contract manufacturing facility in Halle, Germany. The company now has four dedicated lyophilizers and over 1,100 sq. ft.
To freeze-dry clients’ cancer therapy drugs, two large-scale lyophilization units were added. The expansion also includes technologies to handle organic solvents, including a fully automated loading cart and in-process quality analysis technology. The cart navigates in the building with sensors, transporting the cytotoxic vials from filling without human attendance, and auto-loads the freeze driers.
“Our experience in barrier isolators enabled us to realize this cutting edge technology while considering specific customer requests,” says Thomas Julien, director of manufacturing. “By using the latest technology, we eliminate human exposure to the cytotoxics, and reduce contamination-risk of the products.”